Hydrogel-based resiquimod STM-416

{
  "id": "MLC-T-ONC-014266",
  "term": "Hydrogel-based resiquimod STM-416",
  "field": "Oncology and biomedicine",
  "definition": "An injectable biodegradable hydrogel-based, intra-tumoral extended-release (ER) formulation containing the imidazoquinolinamine resiquimod, a Toll-like receptor (TLR) 7 and 8 agonist, with potential immunostimulating and antineoplastic activities. Upon intra-tumoral administration at the site and time of surgery involving transurethral resection of bladder tumor, the hydrogel-based resiquimod STM-416 locally releases resiquimod for an extended period and binds to TLR7 and 8, which are found mainly on dendritic cells (DCs), macrophages, and B lymphocytes, and activates the TLR signaling pathway. This results in the induction of the nuclear translocation of transcription activator nuclear factor kappa-B (NF-kB) and activation of other transcription factors. This leads to the induction of NF-kB-dependent genes and increases cytokine production, especially interferon-alpha (INF-a), which results in the enhancement of T-helper 1 (Th1) immune responses. Activation of DCs also results in the activation of cytotoxic T-lymphocyte (CTL) and B-lymphocyte immune responses. This may cause tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the immune system.",
  "synonyms": [
    "resiquimod-containing hydrogel STM-416"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/hydrogel-based-resiquimod-stm-416/"
}